Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study

Crinetics Pharmaceuticals Inc CRNX released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for acromegaly and CS. Carcinoid syndrome occurs when a rare cancerous tumor, called a…#phase2 #scottstruthers #crinetics #fda #enrollment
Source: Reuters: Health - Category: Consumer Health News Source Type: news